Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 162 pages

Showing 101 - 150


leukemia

Dactinomycin Produces Durable Response in Patient With NPM1-Mutant AML

As reported by Falini et al in a letter to The New England Journal of Medicine, dactinomycin treatment resulted in morphologic and molecular complete remission ongoing at 14 months in a patient with NPM1-mutant acute myeloid leukemia (AML). NPM1-mutated AML may account for one-third of AML in...

leukemia

Ofatumumab Maintenance Improves Progression-Free Survival in Responders to Second- or Third-Line CLL Treatment

In an interim analysis of the phase III PROLONG trial reported in The Lancet Oncology, van Oers et al found that maintenance therapy with ofatumumab (Arzerra) prolonged progression-free survival vs observation in patients with chronic lymphocytic leukemia in complete or partial remission after...

leukemia
myelodysplastic syndromes
issues in oncology

Study Explores Link Between Allele Expression and Risk of Graft-vs-Host Disease in Transplant Recipients

In a study reported in The New England Journal of Medicine, Petersdorf et al found a greater risk of acute graft-vs-host disease among hematopoietic cell transplant recipients with the high-expression rs9277534G allele linked to mismatched HLA-DPB1 who received transplants from donors with the...

leukemia
issues in oncology

Persistent Leukemia-Associated Mutations After Induction Therapy Predict Poorer Outcome in AML

In a study reported in JAMA, Klco et al found that persistence of leukemia-associated mutations in ≥ 5% of bone marrow cells at remission predicted poorer outcome among patients with acute myeloid leukemia (AML), including those with intermediate-risk disease. Study Details In the study,...

leukemia

BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia

In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...

leukemia

No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML

In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...

leukemia
lymphoma
survivorship

Long-Term Follow-Up Suggests No Detrimental Survival Effect of Dexrazoxane in Pediatric Patients With Leukemia or Lymphoma

In an analysis of Children’s Oncology Group (COG) trials reported in the Journal of Clinical Oncology, Chow et al found that dexrazoxane use did not appear to be associated with poorer survival among pediatric patients with leukemia or lymphoma in long-term follow-up. Study Details The...

leukemia
issues in oncology

DNMT3A Mutations Predict Poorer Outcome in Younger Adults With AML Irrespective of NPM1 Genotype, but Type of Mutation Matters

In a UK study reported in the Journal of Clinical Oncology, Gale et al found that presence of DNMT3A mutations was associated with poorer prognosis in young adults with cytogenetic intermediate-risk acute myeloid leukemia (AML) irrespective of the presence of NPM1 mutation. Poorer outcome was found ...

leukemia

Addition of Ofatumumab to Chlorambucil Increases Progression-Free Survival in Previously Untreated CLL Patients Who Are Not Candidates for Fludarabine

In the phase III COMPLEMENT 1 trial reported in The Lancet, Hillmen et al found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chronic lymphocytic leukemia (CLL) who were not considered candidates...

leukemia

Single-Center Experience Indicates Relatively Good Prognosis After Allogeneic Stem Cell Transplantation Failure in CLL

In a retrospective single-center study reported in Journal of Clinical Oncology, Rozovski and colleagues found that chronic lymphocytic leukemia (CLL) patients with disease progression after allogeneic stem cell transplantation had a relatively good prognosis, with apparent benefit of salvage...

leukemia

Less Than 95% Adherence to Mercaptopurine Maintenance Associated With Nearly Threefold Increased Risk of Relapse in Pediatric ALL

In a Children’s Oncology Group study (COG-AALL03N1) reported in JAMA Oncology, Bhatia et al found that < 95% adherence to mercaptopurine treatment was associated with a nearly threefold increase in the risk of relapse in children with acute lymphoblastic leukemia (ALL). Among adherent...

leukemia

No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML

In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...

leukemia

No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL

In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...

leukemia

Factors in Ibrutinib Discontinuation in Patients With Chronic Lymphocytic Leukemia

In a single-center study reported in JAMA Oncology, Maddocks et al found that Richter’s transformation accounted for early progression-related discontinuation of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and that CLL progression but not Richter’s...

leukemia

Ibrutinib Active in Previously Untreated and Relapsed/Refractory CLL With TP53 Aberrations

In a phase II study reported in The Lancet Oncology, Farooqui et al found that single-agent ibrutinib (Imbruvica) had good activity in patients with previously untreated or relapse/refractory chronic lymphocytic leukemia (CLL) with TP53 aberrations. Study Details In this single-arm trial, 51...

leukemia
issues in oncology

Allogeneic Stem Cell Transplantation Prolongs Recurrence-Free Survival in NPM1-Mutant AML

In an analysis of the Study Alliance Leukemia (SAL) AML 2003 trial reported in the Journal of Clinical Oncology, Röllig et al found that allogeneic stem cell transplantation significantly prolonged recurrence-free survival in patients with NPM1-mutant acute myeloid leukemia (AML). NPM1...

leukemia

Bispecific CD19-Directed CD3 T-Cell Engager Blinatumomab Active in Adults With Relapsed/Refractory B-Cell Precursor ALL

In a phase II study reported in The Lancet Oncology, Topp et al found that the bispecific CD19-directed CD3 T-cell engager (BiTE) blinatumomab (Blincyto) was highly active in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab binds to CD19 expressed ...

leukemia

Anti-CD19 Bispecific T Cell Engager Blinatumomab Shows Activity in Relapsed/Refractory B-Precursor ALL

In a phase II study reported in the Journal of Clinical Oncology, Topp et al found that the bispecific T-cell engager (BiTE) antibody blinatumomab produced a high response rate in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). BiTEs induce a transient cytolytic ...

leukemia

CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory ALL

In a study reported in The New England Journal of Medicine, Maude et al reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Study Details In the...

leukemia

New Findings in Acute Promyelocytic Leukemia

Three studies reported in the Journal of Clinical Oncology provide information on maintenance treatment with the synthetic retinoid tamibarotene in acute promyelocytic leukemia, potential implications of QT interval prolongation related to arsenic trioxide (Trisenox), and potential health-related...

leukemia

Promising Activity of Ibrutinib Plus Rituximab in High-Risk CLL

In a phase II trial reported in The Lancet Oncology, Burger et al found that the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) showed promising activity and an encouraging safety profile in patients with previously treated or untreated high-risk chronic lymphocytic leukemia (CLL)....

leukemia

Adding Gemtuzumab Ozogamicin to Chemotherapy Improves Event-Free Survival but Not Overall Survival in Children and Adolescents With De Novo AML

In a Children’s Oncology Group phase III trial reported in the Journal of Clinical Oncology, Gamis et al found that the addition of gemtuzumab ozogamicin (Mylotarg), an immunoconjugate targeting CD33, resulted in significantly prolonged event-free survival but not overall survival when added...

leukemia

Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML

In a letter to the Journal of Clinical Oncology, Richter et al describe a potential tyrosine kinase inhibitor withdrawal syndrome characterized by musculoskeletal pain after stopping tyrosine kinase inhibitor treatment for chronic myeloid leukemia (CML). Onset After Tyrosine Kinase Inhibitor...

hematologic malignancies
leukemia

Minimal Residual Disease–Based Risk-Directed Therapy Is Effective in Children With BCR-ABL1–Like B-Cell ALL

BCR-ABL1–like acute lymphoblastic leukemia (ALL), a recently identified B-cell ALL subtype associated with poor outcome, has a gene-expression profile similar to BCR-ABL1–positive disease without the presence of the BCR-ABL1 fusion protein. In a retrospective analysis reported in the...

leukemia
survivorship

Excess Risk of Chronic Late Effects of Treatment in Children With Standard-Risk ALL

Given the changes in treatment of children with acute lymphoblastic leukemia (ALL), the risk of late effects in those treated with current protocols may be different from that in children treated decades ago. In a study of survivors of childhood standard-risk ALL reported in The Lancet Oncology,...

leukemia

Event-Free Survival Benefit, Greater Toxicity of Augmented Postremission Therapy for Children/Young Adults With High-Risk Acute Lymphoblastic Leukemia

In a UK phase III trial (UKALL 2003) reported in The Lancet Oncology, Vora et al found that augmented postremission therapy provided an event-free survival benefit at the cost of increased toxicity in children and young adults with clinical standard- or intermediate-risk but minimal residual...

leukemia

First-Line Lenalidomide Plus Rituximab Is Safe and Effective in Older and Younger CLL Patients, Phase II Study Shows

The combination of lenalidomide (Revlimid) and rituximab (Rituxan) has shown synergistic activity in chronic lymphocytic leukemia (CLL) preclinical models. In a CLL Research Consortium phase II study of the combination in treatment-naive patients reported in the Journal of Clinical Oncology, James...

leukemia
issues in oncology

Ibrutinib Resistance Mutations Identified in CLL Patients

Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase that was recently approved for treatment of chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy. A small proportion of CLL patients have been observed to relapse during ibrutinib treatment, ...

leukemia

No Overall Survival Improvement With Elacytarabine vs Investigator Choice in Patients With Relapsed/Refractory AML

Current treatment options for relapsed/refractory acute myeloid leukemia (AML), which carries a very poor prognosis, are generally ineffective. In a phase III trial (CLAVELA) reported in the Journal of Clinical Oncology, Roboz et al found that elacytarabine, a novel elaidic acid ester of...

leukemia
issues in oncology

Mutations Associated With Arsenic Resistance in Acute Promyelocytic Leukemia

In a letter to The New England Journal of Medicine, Zhu et al described identification of resistance mutations in acute promyelocytic leukemia patients receiving arsenic trioxide (Trisenox) and all-trans retinoic acid (ATRA) therapy. The direct-binding targets of arsenic trioxide in the...

leukemia

Good Prognosis for High-Risk Ph-Negative ALL With Chemotherapy After Early Cytologic Response and Low Minimal Residual Disease Level on Flow Cytometry

In a Spanish trial (PETHEMA ALL-AR-03) reported in the Journal of Clinical Oncology, Ribera et al found high disease-free and overall survival rates with delayed consolidation and maintenance chemotherapy in high-risk Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL)...

leukemia

Novel Prognostic Indices Validated for Cytogenetically Normal Acute Myeloid Leukemia

Cytogenetically normal acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. As reported in the Journal of Clinical Oncology, Pastore et al have developed a widely applicable prognostic model for cytogenetically normal AML that combines established patient and ...

leukemia
issues in oncology

IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia

In a study reported in the Journal of Clinical Oncology, Russell et al found that immunoglobulin heavy chain (IGH@) translocations were present in a substantial proportion of younger patients with acute lymphoblastic leukemia (ALL), including those with B-cell precursor ALL. However, IGH@...

leukemia
myelodysplastic syndromes

Prolonged Administration of Azacitidine Improves Response in Myelodysplasia, Less So in Combination With Entinostat

In the phase II US Leukemia Intergroup Trial E1905 reported in the Journal of Clinical Oncology, Prebet et al found that prolonged administration of lower-dose azacitidine produced a high response rate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) with myelodysplastic...

leukemia

Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia

In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...

leukemia
issues in oncology

Methotrexate-Induced Neurotoxicity Does Not Preclude Rechallenge in Children With ALL

In a study reported in the Journal of Clinical Oncology, Bhojwani et al from St. Jude Children’s Research Hospital assessed clinical, pharmacokinetic, and genetic risk factors for methotrexate-related clinical neurotoxicity and asymptomatic leukoencephalopathy in children with acute...

leukemia

Use of Intravenous Pegaspargase in Adapted Pediatric Regimen Is Feasible in Adults With Newly Diagnosed ALL

Asparaginase treatment, standard in pediatric acute lymphoblastic leukemia (ALL) regimens, is excluded or used for shorter durations in treatment of adults with ALL due to risk of toxicity. In a study reported in Journal of Clinical Oncology, Douer et al evaluated a pegaspargase (Oncaspar) dosing...

issues in oncology
hematologic malignancies
leukemia

CD49d-Positivity Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in CLL

In a study reported in the Journal of Clinical Oncology, Bulian et al found that CD49d-positive chronic lymphocytic leukemia (CLL) patients have significantly poorer overall survival and treatment-free survival and that CD49d status is the strongest flow cytometry–based predictor of overall...

leukemia

Alternative Mechanism of Action Suggested for Vemurafenib in Hairy Cell Leukemia With BRAF V600E Mutation

The finding that the BRAF V600E mutation is present in nearly all cases of hairy cell leukemia has resulted in the use of BRAF inhibitors to treat chemotherapy-resistant disease, with good responses to vemurafenib (Zelboraf) being observed. BRAF inhibition has been thought to result in...

leukemia

Adding Idelalisib to Rituximab Improves Progression-Free and Overall Survival in Patients With Difficult-to-Treat, Relapsed CLL

Use of standard chemotherapy is difficult in patients with relapsed chronic lymphocytic leukemia (CLL) who have significant coexisting medical conditions. In a phase III trial reported in The New England Journal of Medicine, Furman et al found that the combination of idelalisib, an oral inhibitor...

skin cancer
leukemia

Advanced Rai Stage Predicts Poor Outcome of Skin Cancer in CLL

Chronic lymphocytic leukemia (CLL) is associated with increased risk of skin cancer. In a study reported in JAMA Dermatology, Velez et al attempted to determine whether progression of CLL indicated by advanced Rai stage is associated with worse skin cancer outcomes. They found that risk of death...

leukemia
issues in oncology

Seven-Gene Score Incorporating Methylation and Expression Distinguishes AML Risk Groups

In a study reported in the Journal of Clinical Oncology, Marcucci et al assessed whether including epigenetic changes—ie, DNA methylation—as molecular risk factors could improve risk stratification in acute myeloid leukemia (AML). They found that a seven-gene score integrating DNA...

leukemia

Superior Progression-Free Survival With Obinutuzumab/Chlorambucil vs Rituximab/Chlorambucil in Previously Untreated CLL With Coexisting Conditions

Obinutuzumab (Gazyva) is a glycoengineered type 2 anti-CD20 antibody that appears to exhibit increased activity against chronic lymphocytic leukemia cells (CLL), with increased antibody-dependent cellular cytotoxicity and reduced complement-dependent cytotoxicity, compared with rituximab (Rituxan). ...

leukemia

Ibrutinib Promising as Initial Therapy for Elderly Patients With CLL in Phase IB/II Trial

Chemoimmunotherapy has produced improved response and survival in young patients with chronic lymphocytic leukemia (CLL), but its use in elderly patients has been limited by myelosuppression and infection. In a phase IB/II study reported in The Lancet Oncology, O’Brien et al assessed the use...

leukemia

Good Results Using Loss of Major Molecular Response as Criterion for Restarting Tyrosine Kinase Inhibitor Therapy in CML

Many patients with chronic-phase chronic myelogenous leukemia (CML) in complete molecular response have molecular relapse after discontinuation of imatinib (Gleevec) treatment. In a French multicenter observational study reported in the Journal of Clinical Oncology, Rousselot et al assessed the...

leukemia
issues in oncology

Higher Copayment Associated With Greater Discontinuation of and Nonadherence to Tyrosine Kinase Inhibitor Treatment in CML

The availability of the tyrosine kinase inhibitor imatinib (Gleevec) has dramatically increased survival in chronic myeloid leukemia (CML). Nonadherence to therapy with imatinib and other tyrosine kinase inhibitors is associated with disease progression and treatment resistance. In a study reported ...

leukemia

Matched-Pairs Analysis Shows Better Survival With Allogeneic Transplantation vs Conventional Chemotherapy in Postremission Therapy for AML

In a prospective matched-pairs analysis reported in the Journal of Clinical Oncology, Stelljes et al in the German AML Cooperative Group compared outcomes with allogeneic stem cell transplantation vs conventional postremission chemotherapy in patients aged < 60 years with acute myeloid leukemia...

leukemia

Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years

In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...

leukemia
survivorship

Persistent Significant Neurocognitive Impairment in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

In a study reported in the Journal of Clinical Oncology, Kevin R. Krill, PhD, and colleagues from St. Jude Children’s Research Hospital assessed neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia (ALL). They found pervasive significant impairment across...

hematologic malignancies
leukemia
issues in oncology

Novel Oncogenetic Classifier Identifies Low- and High-Risk Patients With Adult T-Cell Acute Lymphoblastic Leukemia

The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported significantly better outcome in T-cell acute lymphoblastic leukemia (ALL) harboring NOTCH1 or FBXW7 (N/F) mutations, although relapse was still observed in one-third of patients with N/F-mutated T-cell ALL. In a ...

Advertisement

Advertisement



Advertisement